Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRL3-Zumab in Advanced Solid Cancers
NCT07290088Phase 3Recruiting
- Sponsor
- Intra-ImmuSG
- Start
- Jan 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of PRL3-zumab in solid tumor, sponsored by Intra-ImmuSG. Started Jan 2023; status: recruiting.
02
Drugs
PRL3-zumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07290088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07290088.